In particular, CXCR4 was increased by the treatment with Bafetinib and Ibrutinib, while CCR7 was reduced by Bafetinib; at the same time, CXCR5 was affected only by Ibrutinib and the two kinase inhibitors do not show a significant influence on CXCR3 expression, suggesting that their action may be carried out mostly by the receptors involved in the process of CLL homing. This evidence concerns the gene CCR7 and B-cell chronic lymphocytic leukemia.